Strand launches genomic profiling service in India

Test provides standard-of-care tissue-specific results for non-small cell lung (NSCLC), breast, and colon carcinomas within 10 working days

images52285

(Photo Courtesy: www.aacc.org)

Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower personalized cancer care, announced the India launch of StrandAdvantage, a cancer tissue-specific genomic profiling service to provide oncologists with clinically actionable and timely results for first-line therapy decisions.

The newly launched service accelerates the analysis of therapeutically actionable cancer genes in solid tumors, and matches them to relevant National Comprehensive Cancer Network (NCCN)-recommended cancer therapies, enabling timely decisions for patient-specific treatments.

StrandAdvantage provides oncologists with clinically actionable tissue-specific results for non-small cell lung, breast, and colon carcinomas in a standard-of-care report within 10 working days.

Strand's NGS-based genomic profiling service provides a comprehensive view of genomic changes in an easy-to-read report enabling oncologists to make optimized, first-line treatment decisions.

The service also provides an extended investigational 'on-demand' report after 15 days for cases that require a complete workup of all major gene variants and pathways known to be impacted by existing targeted therapies.

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X